Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
Decision brief
Answer first · skim in under a minute
Daraxonrasib nearly doubled overall survival in a Phase III trial for pancreatic ductal adenocarcinoma, an unprecedented outcome. This article analyzes the clinical data, regulatory implications, and strategic impact for pharma BD and investors.
Revolution Medicines stock catalysts center on daraxonrasib: Phase 3 RASolute 302 nearly doubled median overall survival versus chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma, with a hazard ratio of 0.40 in the intent-to-treat population.
Contents10 sections
Key Takeaways
- ITT median OS: 13.2 months daraxonrasib vs 6.7 months chemotherapy; HR 0.40; p<0.0001 (April 13, 2026 topline).
- Oral 300 mg once daily RAS(ON) multi-selective inhibitor versus investigator’s-choice IV chemo in RASolute 302 (NCT06625320).
- Company plans global regulatory submissions, including a U.S. NDA path under a Commissioner’s National Priority Voucher.
- More than 90% of PDAC tumors harbor RAS mutations; the trial enrolled RAS G12–mutant and RAS wild-type / unidentified cases.
What did the Phase 3 topline show?
On April 13, 2026, Revolution Medicines reported that RASolute 302 met primary and key secondary endpoints for progression-free and overall survival. In the overall intent-to-treat population, median OS reached 13.2 months on daraxonrasib versus 6.7 months on chemotherapy.
The hazard ratio of 0.40 (p<0.0001) is the figure BD teams will underwrite first. Full subgroup tables for RAS G12 alleles still matter for label negotiations. Source: GlobeNewswire topline release.
How was RASolute 302 designed?
RASolute 302 is a global, randomized Phase 3 trial in previously treated metastatic PDAC. Patients received oral daraxonrasib 300 mg daily or investigator’s choice of standard cytotoxic regimens. Primary endpoints were BICR-assessed PFS and OS in RAS G12–mutant tumors; secondary endpoints included PFS and OS in all enrolled patients.
The protocol is listed as NCT06625320. Enrolling both RAS-mutant and RAS-unidentified tumors tests whether multi-selective RAS(ON) inhibition travels beyond the G12-enriched primary analysis set.
Why is the mechanism strategically important?
Pancreatic cancer is among the most RAS-addicted major tumor types, with company materials citing RAS mutations in more than 90% of patients. Daraxonrasib is positioned as a multi-selective inhibitor of RAS(ON) proteins rather than a single-allele covalent KRAS G12C drug.
That breadth is the commercial thesis: one oral agent covering G12D/V/R and related drivers that dominate PDAC. Reuters also summarized the survival doubling for general audiences in May 2026 coverage of the dataset.
See Reuters’ report for contemporaneous market framing alongside the primary wire release.
Regulatory and BD implications
Revolution Medicines said the first interim analysis made PFS and OS results final and that it intends to submit the package to FDA and other regulators. The company also referenced FDA Breakthrough Therapy and Orphan Drug designations for previously treated metastatic PDAC with G12 mutations, plus selection for the Commissioner’s National Priority Voucher pilot.
For BD, the near-term questions are manufacturing scale, CNS and hepatic safety in broader use, and whether earlier-line PDAC or NSCLC Phase 3 programs dilute focus. Peak-sales models should separate second-line metastatic PDAC from speculative earlier-line expansions until those trials read out.
What remains unproven?
Topline OS doubling does not guarantee first-line superiority, adjuvant utility, or combination benefit with chemotherapy or checkpoint inhibitors. Peer-reviewed full tables (ASCO plenary / journal publication) should be checked for crossover, subsequent therapy imbalance, and quality-of-life instruments before calling the result practice-changing in every geography.
Daraxonrasib remains investigational. No marketing approval is claimed in this analysis.
Related NovaPharma coverage
- BioNTech pancreatic cancer mRNA vaccine trial
- Pancreatic cancer disease hub
- Revolution Medicines company profile
How investors should read Revolution Medicines stock catalysts
Revolution Medicines stock narrative after RASolute 302 hinges on whether the OS hazard ratio holds across RAS G12 alleles and whether regulators accept the ITT framing for a broad label. A 13.2 versus 6.7 month median OS split is rare in previously treated metastatic PDAC, but label language will likely emphasize molecular subsets and prior therapy definitions.
Commercial models should also stress-test oral adherence at 300 mg daily against IV chemo discontinuation patterns. If real-world dose intensity falls, the trial’s hazard ratio may compress. Manufacturing capacity for a multi-selective RAS(ON) inhibitor becomes a gating item once NDA timing is public.
Finally, keep NSCLC and earlier-line PDAC Phase 3 programs on a separate valuation tree. The April 13, 2026 topline validates the platform in second-line-plus metastatic PDAC; it does not automatically transfer to adjuvant settings or KRAS G12C–crowded lung niches without those readouts.
Frequently Asked Questions
What survival benefit did daraxonrasib show in RASolute 302?
In the intent-to-treat population, median overall survival was 13.2 months with once-daily oral daraxonrasib versus 6.7 months with investigator’s-choice chemotherapy, hazard ratio 0.40 (p<0.0001), per Revolution Medicines’ April 13, 2026 topline release.
Which trial and dose were studied?
RASolute 302 (NCT06625320) randomized previously treated metastatic PDAC patients to 300 mg daraxonrasib once daily or standard cytotoxic chemotherapy. Primary endpoints included PFS and OS in RAS G12–mutant tumors, with ITT PFS/OS as key secondary endpoints.
What is the regulatory path next?
The company said it intends to include the data in a future FDA NDA submission under a Commissioner’s National Priority Voucher pathway and to seek other global filings. Daraxonrasib is not yet approved.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for daraxonrasib.
Unlock full calendar →Revolution Medicines pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
